Amid the rising rate of multidrug-resistant infections, The Medicines Co. launched a pivotal program testing Carbavance, a combination anti-infective, against carbapenem-resistant Enterobacteriaceae (CRE), which the Centers for Disease Control and Prevention has called one of the most deadly gram-negative pathogens.